

[Redacted text block]

[Redacted text block]

??????

[Redacted text block]

[Redacted text block]

I
I
p

[Redacted text block]

p

[Redacted text block]

[Redacted text block]

??????

[Redacted text block]

[Redacted text block]

Data Monitoring Committee, DMC

<input type="checkbox"/> Bayesian method	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
<input type="checkbox"/> Simulation method	<input type="checkbox"/> <input type="checkbox"/>

????

1. . . 2020.
2. Bauer P, Köhne K. Evaluation of experiments with adaptive interim analyses. *Biometrics*.1994; 50:1029-1041. corrections. *Biometrics*.1996; 52:380.
3. Bauer P, Kieser M. Combining different phases in the development of medical treatments within a single trial. *Statistics in Medicine*.1999; 18: 1833-1848.
4. Bauer P, Posch M. Letter to the Editor. Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections by H. Schaefer and H.-H. Mueller, *Statistics in Medicine* 2001; 20: 3741-3751. *Statistics in Medicine*.2004; 23: 1333-1335.
5. Chang M. Adaptive design method based on sum of p-values. *Statistics in Medicine*.2007; 26:2772-2784.
6. Chen C, Li X, Li W, Beckman RA. Adaptive Expansion of Biomarker Populations in Phase 3 Clinical Trials. *Contemporary Clinical Trials*.2018; 71:18-85.
7. Chen C, Anderson K, Mehrotra DV, Rubin EH and Tse A. A 2-in-1 Adaptive Phase 2/3 Design for Expedited Oncology Drug Development. *Contemporary Clinical Trials*.2018; 64:238-242.
8. Chen JYH, DeMets DL, Lan GKK. Increasing the sample size when the unblinded interim results is promising. *Statistics in Medicine*.2004; 23:1023-1038.
9. Chow SC. Complex innovative design for NASA clinical trials. *Academic Journal of Gastroenterology & Hepatology*.2020; 2: 1-9.
10. Chow SC, Chang M. *Adaptive Design Methods in Clinical Trials*. CRC Press, 2nd edition.2011.
11. Chow SC, Lin M. Analysis of two-stage adaptive seamless trial design. *Pharmaceutica Analytica Acta*.2015; 6: 341-440.
12. Chow SC, Shao J, Wang H, Lokhnygina Y. *Sample size calculations in clinical research*. Chapman & Hall/CRC, 3rd edition.2018.
13. Chow SC, Tu YH. On two-stage seamless adaptive design in clinical trials. *Journal of Formosan Medical Association*.2008; 107: s1-59.

14. Cui L, Hung HMJ, Wang SJ. Modification of sample size in group sequential clinical trials. *Biometrics*.1999; 55:853-857.
15. Cui L, Zhang L. On the efficiency of adaptive sample size design. *Statistics in Medicine*.2019;38:933-944.
16. Friede T, Kieser M. Sample size recalculation in internal pilot study designs: a review. *Biometrical Journal*.2006; 48:537-555.
17. Friede T, Parsons N, Stallard N. A conditional error function approach for subgroup selection in adaptive clinical trials. *Statistics in Medicine*.2012; 31:4309-4320.
18. Friede T, Stallard Nigel. A comparison of methods for adaptive treatment selection. *Biometrical Journal*.2008; 50:767-781.
19. Gould AL. Interim analyses for monitoring clinical trials that do not materially affect the Type I error rate. *Statistics in Medicine*.1992; 14:1039-1051.
20. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. *Biometrika*.1988; 75: 800-802.
21. Howard DR, Brown JM, Todd S, Gregory WM. Recommendations on multiple testing adjustment in multi-arm trials with a shared control group. *Statistical Methods in Medical Research*.2018; 27:1513-1530.
22. Jenkins M, Stone A, Jennison C. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. *Pharmaceutical Statistics*.2011; 10:347-356.
23. Lan KG, DeMets DL. Discrete Sequential Boundaries for Clinical Trials. *Biometrika*.1983; 70:659-663.
24. Lehmacher W, Wassmer G. Adaptive sample size calculations in group sequential trials. *Biometrics*.1999; 55: 1286-1290.
25. Maca J, Bhattacharya S, Dragalin S. et al. Adaptive Seamless Phase II/III Designs Background, Operational Aspects, and Examples. *Drug Information Journal*.2006; 40: 463-474.
26. Marcus R, Peritz E, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. *Biometrika*.1976; 63:655-660.
27. Mehta CR, Pocock SJ. Adaptive increase in sample size when interim results are promising: a practical guide with examples. *Statistics in Medicine*.2001; 30:3267- 3284.
28. Müller HH, Schäfer H. Adaptive group sequential designs for clinical trials: Combining the advantages of adaptive and of classical group sequential approaches. *Biometrics*.2001; 57:886-891.

29. Müller HH, Schäfer H. A general statistical principle for changing a design any time during the course of a trial. *Statistics in Medicine*.2004; 23:2497–2508.
30. O'Brien PC, Fleming TR. A Multiple Testing Procedure for Clinical Trials. *Biometrics*.1979; 549–556.
31. Pocock SJ. Group Sequential Methods in the Design and Analysis of Clinical Trials. *Biometrika*.1977; 64:191–199.
32. Proschan MA, Hunsberger SA. Designed extension of studies based on conditional power. *Biometrics*.1995; 51:1315–1324.
33. Rosenblum M, Van Der Laan MJ. Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment. *Biometrika*.2011; 98: 845-860.
34. Shih WJ. Sample size re-estimation – a journey for a decade. *Statistics in Medicine*.2001; 20:515-518.
35. Shih WJ, Li G, Wang Y. Methods for flexible sample-size design in clinical trials: Likelihood, weighted, dual test, and promising zone approaches. *Contemporary Clinical Trials*.2016; 47: 40-48.
36. Simes RJ. An improved Bonferroni procedure for multiple tests of significance. *Biometrika*.1986; 73:751–754.
37. Stallard N, Hamborg T, Parsons N, Friede T. Adaptive designs for confirmatory clinical trials with subgroup selection. *Journal of Biopharmaceutical Statistics*.2014; 24:168–187.
38. Wang SJ, Hung HMJ, O'Neill RT. Adaptive patient enrichment designs in therapeutic trials. *Biometrical Journal*.2009; 51:358–374.
39. Wassmer G, Brannath W. Group sequential and confirmatory adaptive designs in clinical trials. Springer,2016.
40. Wu PS, Lin M, Chow SC. On sample size estimation and re-estimation adjusting for variability in confirmatory trials. *Journal of Biopharmaceutical Statistics*.2016; 26:44-54.
41. Zhang JJ, Blumenthal G, He K, Tang S, Cortazar P, Sridhara R. Overestimation of the effect size in group sequential trials. *Clinical Cancer Research*.2012; 18: 4872-4876.
42. Zheng J, Chow SC. Criteria for dose-finding in two-stage seamless adaptive design. *Journal of Biopharmaceutical Statistics*.2019; 29: 908-919.

Revision #2

Created 2025-12-13 02:27:47 UTC by Colin Wang

Updated 2025-12-13 03:14:43 UTC by Colin Wang